Between January 2016 and June 2021, 24,626 people died from opioid toxicity in Canada. A key driver of this ongoing public health crisis has been the infiltration of illicitly manufactured fentanyl and other dangerous adulterants into the unregulated drug supply. Although a range of educational, harm reduction and substance use disorder (SUD) treatment interventions have been implemented and expanded in response, these efforts have not been sufficient, and the number of deaths from drug poisoning continues to rise. Furthermore, a substantial proportion of people do not access conventional treatments; for instance, only a minority of patients with opioid use disorder regularly receive treatment medications. Emerging evidence also suggests that the changing drug supply has negatively affected the effectiveness of these medications, including the efficacy of buprenorphine among people using fentanyl compared with those using heroin. An additional concern is unintentional exposure to fentanyl among people who use substances such as stimulants and the emergence of other contaminants such as benzodiazepines.

This reality has prompted calls for the provision of a legal and regulated source of psychoactive substances, known as “safe supply,” particularly low-barrier, flexible options that meet the diverse needs and goals of people who use drugs.

What is the Safer Alternatives for Emergency Response program?

Operating in Vancouver since April 2021, Safer Alternatives for Emergency Response (SAFER) is a safe supply program that provides substitutes to the toxic drug supply in the form of medications that are prescribed off label. The program is operated by a nonprofit organization (PHS Community Services Society) in partnership with Vancouver Coastal Health, and is funded through Health Canada’s Substance Use and Addiction Program. A multidisciplinary team of physicians, nurses, pharmacists, social workers and people with lived or living experience of substance use oversees the program. The approach adopted at SAFER can be viewed as an extension of the use of medications as treatment for SUDs, such as opioid agonist therapy (OAT). However, in contrast to OAT, which is often prescribed with a goal of abstinence, the primary goal of SAFER is to prevent overdose and other harms by decreasing reliance on the unpredictable, unregulated drug market. Medications provided at SAFER include those with mind- and body-altering effects that are often desired by people who use drugs but are typically accessible only via unregulated drugs and are not provided by conventional treatments such as OAT.

Who is eligible?

Eligibility for SAFER is based on ongoing use of substances and vulnerability to their associated harms. At intake, participants are assessed to determine appropriate medication options and potential need for precautions owing to medical conditions that affect tolerability of SAFER medications, factors that confer additional vulnerability (such as pregnancy or young age) and concurrent use of substances such as alcohol that require additional counselling. Although there are no absolute contraindications to participation, the program emphasizes identifying the appropriateness of the intervention, recognizing participant autonomy and facilitating connection to evidence-based treatment for SUDs when this is aligned with participant-defined goals.
Enrolled participants can access medications, including opioids such as hydromorphone and fentanyl, that substitute the unregulated substances they are currently consuming. Various formulations are available, including injectable, sublingual, oral and transdermal formulations. A notable and novel feature of the SAFER program is that it offers fentanyl, providing a direct substitute to the primary opioid in the local unregulated drug supply, but of known potency and without dangerous adulterants. Participants can choose between a titration schedule that starts with lower doses to ensure tolerance before increasing to a higher range, or a fixed dose that is taken as needed. Given the increasing rate of overdose deaths involving stimulants in Canada, and the limited treatment options for stimulant use disorder, prescribed psychostimulants are also available, including methylphenidate and dextroamphetamine.

For each medication, a unique dosage protocol is largely overseen by nursing staff, unlike OAT, which typically requires physician assessment before dosage changes. Initial doses start at a standardized level to ensure tolerance, but are then adjusted to achieve a desired effect, thereby promoting participant autonomy in decision-making around substance use. Other program features intended to improve engagement include allowing on-site use of unregulated substances, meaning that the program also functions as a supervised consumption service, and providing a demedicalized physical space staffed by peer support workers. Unlike OAT, which is typically administered once daily and is cancelled after a few consecutive missed doses, SAFER does not have a predetermined schedule for accessing medications, which allows participants to return multiple times per day or to be absent for periods of time. In contrast with most other existing safe supply options, SAFER participants are not required to remain on OAT concurrently. By decoupling these interventions, the focus of SAFER is on harm reduction, promotion of participant autonomy and improvement of participant–provider relationships.

The SAFER program is integrated with health care and social services, and participants have access to on-site primary care from providers trained in addiction medicine. It is also colocated with a low-barrier overdose prevention site where supplies such as syringes, take-home naloxone kits and drug-checking services are available.

What are the potential harms?

Safe supply may carry a risk of diversion, and this concern is reflected in the inclusion of monitoring and dispensation recommendations within current guidance for prescription of pharmaceutical alternatives.7 Initially all SAFER participants are asked to use the substances provided on site, and to complete urine drug tests to detect potential diversion (e.g., negative screen for prescribed SAFER medications).

A further concern is that providing pharmaceutical alternatives could perpetuate substance use and undermine engagement in treatment. However, the aim of SAFER is to reduce overdose risk and not necessarily to support abstinence unless this is aligned with a participant’s goals. Further, safe supply and treatment for SUDs are not mutually exclusive and can be effectively provided concurrently.

What is the evidence so far?

Previous clinical trials have shown the efficacy of intravenous diacetylmorphine (heroin) and hydromorphone (forms of injectable OAT) for patients not benefiting sufficiently from methadone alone.8,9 In addition, emerging evidence suggests that certain prescription psychostimulants may be effective treatments for stimulant use disorder.10 However, these studies were conducted in highly controlled, medicalized settings before the emergence of fentanyl in the unregulated drug supply, which may affect the effectiveness of the aforementioned medications.

Recent evaluations of tablet hydromorphone distribution programs in Vancouver and London, Ontario, showed improvements in health, economic security and pain management, as well as reduced unregulated drug use.11,12 These evaluations also identified key challenges, including lack of alternative medication options available to program participants.11,12

To date, SAFER has enrolled 58 participants, with a similar number on a wait list until a larger physical space allows for increased capacity. Initial informal assessments suggest that participants note benefits from having new options when conventional forms of treatment and harm reduction have not been efficacious, and program clinicians describe improved chronic disease management and increased medication adherence.

A scientific evaluation of SAFER, funded by Vancouver Coastal Health, will assess the effectiveness of the program in meeting its objectives of reducing risk of overdose and supporting access to the continuum of care (e.g., primary care, harm reduction and SUD treatment), without generating unintended harms. Two of the coauthors (M.C.K. and T.K.) are leading the evaluation, in collaboration with SAFER program operators and with ongoing involvement of partner organizations and people with lived or living experience of substance use. For the evaluation, a prospective cohort of about 200 SAFER participants is being established. Data collection will include baseline and semiannual questionnaires over a 2-year period, which will be confidentially linked to program data and a range of external administrative health databases (e.g., vital statistics, ambulatory care services). In addition, a subset of about 40 cohort participants will participate in in-depth qualitative interviews at baseline and at 3 to 6 months after enrolment. This will allow for longitudinal statistical analyses to examine key outcomes of interest (e.g., nonfatal and fatal overdose, medication adherence, uptake of other services), as well as qualitative investigation of the lived experience of participants to elucidate individual and contextual influences on program engagement and outcomes.

What can be expected in the future?

Although SAFER is initially operating only in Vancouver, similar safe supply programs have been implemented or are being considered in other Canadian settings. Including SAFER, Health Canada has funded 18 safe supply pilot programs since 2019.13 Future research should assess how different features and contexts of such programs (e.g., available medications, delivery models, policy contexts) influence effectiveness. Given strong
consensus among experts that safe supply is among the most promising measures to curb the drug poisoning crisis, it is critical to remove barriers to access, expand coverage, conduct rigorous evaluation and refine delivery approaches to maximize potential impacts.

References

1. Special Advisory Committee on the Epidemic of Opioid Overdoses. Opioids and stimulant-related harms in Canada. Ottawa: Public Health Agency of Canada; modified 2022 Mar. 23. Available: https://health-infobase.canada.ca/substance-related-harms/opioids-stimulants/ (accessed 2022 Feb. 15).

2. Piske M, Zhou H, Min JE, et al. The cascade of care for opioid use disorder: a retrospective study in British Columbia, Canada. Addiction 2020;115:1482-93.

3. Silverstein SM, Danilaityte R, Martins SS, et al. “Everything is not right anymore”: buprenorphine experiences in an era of illicit fentanyl. Int J Drug Policy 2019; 74:76-83.

4. Tyndall M. A safer drug supply: a pragmatic and ethical response to the overdose crisis. CMAJ 2020;192:E986-7.

5. Safe supply concept document. Dartmouth: Canadian Association of People who Use Drugs; 2019. Available: https://zenodo.org/record/5637607#.YmGn6JPMLLB (accessed 2022 Apr. 20).

6. Ahamad K, Bach P, Brar R, et al. Risk mitigation: in the context of dual public health emergencies [interim clinical guidance]. Vancouver: BC Centre on Substance Use; 2020.

7. Oviedo-Joekes E, Brissette S, Marsh DC, et al. Diacetylmorphine versus methadone for the treatment of opioid addiction. N Engl J Med 2009;361:777-86.

8. Oviedo-Joekes E, Ghu D, Brissette S, et al. Hydromorphone compared with diacetylmorphine for long-term opioid dependence: a randomized clinical trial. JAMA Psychiatry 2016;73:447-55.

9. Tardelli VS, Bisaga A, Arcadepani FB, et al. Prescription psychostimulants for the treatment of stimulant use disorder: a systematic review and meta-analysis. Psychopharmacology (Berl) 2020;237:2233-55.

10. Ivsins A, Boyd J, Mayer S, et al. “It’s helped me a lot, just like to stay alive”: a qualitative analysis of outcomes of a novel hydromorphone tablet distribution program in Vancouver, Canada. J Urban Health 2021;98:59-69.

11. Safer Opioid Supply Program: preliminary report. London (ON): London InterCommunity Health Centre; 2021. Available: https://lích.on.ca/wp-content/uploads/2022/01/2021-SOS-Evaluation-Full.pdf (accessed 2022 Feb. 15).

12. Ivsins A, Boyd J, Mayer S, et al. Barriers and facilitators to a novel low-barrier hydromorphone distribution program in Vancouver, Canada: a qualitative study. Drug Alcohol Depend 2020;216:108202.

13. Federal actions on opioids to date. Ottawa: Health Canada; modified 2022 Mar. 23. Available: https://www.canada.ca/en/health-canada/services/opioids/federal-actions/overview.html (accessed 2022 Feb. 15).

Competing interests: Sukhpreet Klaire is a physician and Christy Sutherland is the medical director for the PHS Community Services Society, a nonprofit organization that operates the Safer Alternatives for Emergency Response (SAFER) program in partnership with Vancouver Coastal Health. Christy Sutherland also reports grants from Health Canada and consulting fees from AIDS Vancouver Island, outside the submitted work. No other competing interests were declared.

This article has been peer reviewed.

Affiliations: British Columbia Centre on Substance Use (Klaire, Kerr, Kennedy); Department of Family Practice (Klaire, Sutherland), University of British Columbia; PHS Community Services Society (Klaire, Sutherland); Department of Medicine (Kerr), University of British Columbia, Vancouver, BC; School of Social Work (Kennedy), University of British Columbia (Okanagan), Kelowna, BC

Contributors: Christy Sutherland, Thomas Kerr and Mary Clare Kennedy conceived and designed the work. Sukhpreet Klaire wrote the initial draft of the manuscript. All of the authors revised it critically for important intellectual content, gave final approval of the version to be published and agreed to be accountable for all aspects of the work.

Content licence: This is an Open Access article distributed in accordance with the terms of the Creative Commons Attribution (CC BY-NC-ND 4.0) licence, which permits use, distribution and reproduction in any medium, provided that the original publication is properly cited, the use is noncommercial (i.e., research or educational use), and no modifications or adaptations are made. See: https://creativecommons.org/licenses/by-nc-nd/4.0/

Correspondence to: Sukhpreet Klaire, sukhpreet.klaire@gmail.com

CMAJ invites contributions to Innovations, which highlights recent diagnostic and therapeutic advances. Novel uses of older treatments will also be considered. For publication, the benefits of the innovation, its availability and its limitations must be highlighted clearly. Submit brief evidence-based articles (maximum 1000 words and five references) to http://mc.manuscriptcentral.com/cmaj or email andreas.laupacis@cmaj.ca to discuss ideas.